Towards Healthcare
Biopharmaceutical CDMO Market to Reach USD 46.98 Bn by 2034

Biopharmaceutical CDMO Market Growth Fueled by Advanced Therapies

Market insights predict the global biopharmaceutical CDMO industry will increase from USD 20.55 billion in 2024 to USD 46.98 billion by 2034, achieving a CAGR of 8.73%. The biopharmaceutical CDMO market is expanding due to growth in research and development. North America led the market due to the presence of large biopharmaceutical ecosystems.

  • Insight Code: 6250
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

FAQ's

The biopharmaceutical CDMO market stands at USD 22.34 billion in 2025 and is expected to reach USD 46.98 billion by 2034, growing at a CAGR of 8.73% from 2024 to 2034.

North America is currently leading the biopharmaceutical CDMO market share 41% due to the presence of large biopharmaceutical ecosystems.

The biopharmaceutical CDMO market includes 5 segments such as by service type, by product type, by technology platform, by end user, and by region.

The monoclonal antibodies, recombinant proteins, vaccines, cell & gene therapies, and RNA-based therapies are different types of biologics receiving biopharmaceutical CDMO expertise.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.